Senior Management Team
Chairman, CEO and Co-Founder
Frédéric Cren, an experienced pharmaceutical executive, is CEO and Co-Founder of Inventiva. He has held several key positions in the pharmaceutical industry, the most recent being General Manager – Research with Abbott Labs from 2010 to 2012. Mr. Cren has demonstrated his expertise in the areas of research, development, marketing, strategy and operations through his various roles as Vice-President Strategic Marketing, Vice-President US Operations and member of the Executive Committee of Fournier Laboratories from 2001 to 2005. During this period he was in charge of Fournier’s fenofibrate franchise and of the successful development and launch of TriCor® 145. He subsequently moved up to Head of Business Strategy and Portfolio, Senior Vice-President of the Research Division and member of the Executive Committee of Solvay Pharmaceuticals following the acquisition of Fournier by Solvay in 2005. Prior to joining the pharmaceutical industry, Mr. Cren was a consultant for 8 years with The Boston Consulting Group and a Manager in their healthcare practice. He holds an MBA from INSEAD, a MA from Johns Hopkins University and a Bachelor’s Degree from Paris IX Dauphine.
Consult Frédéric’s profile on LinkedIn
Pierre Broqua, Ph.D.
CSO and Co-Founder
Dr Broqua brings over 25 years of experience in drug discovery and innovative research to Inventiva. Before co-founding Inventiva, he successfully managed numerous research programs leading to the discovery of highly innovative preclinical and clinical compounds, in particular during his tenure at Ferring Pharmaceuticals from 1997 to 2002 and Fournier Laboratories from 2002 to 2005, as Head of Neuroscience for Solvay Pharmaceuticals from 2007 to 2010 and finally as Head of Research for the Abbott Dijon R&D site. One of his most notable achievements was his co-discovery, while head of Pharmacology at Ferring Pharmaceuticals, of the GnRH antagonist Degarelix (now marketed under the brand name Firmagon®). Dr Broqua holds a Ph.D in Pharmacology from the University of Paris Descartes and has a master’s degree in Chemistry and Biochemistry from Université Pierre et Marie Curie, Paris.
Consult Pierre’s profile on LinkedIn
Jean Volatier started his career with PriceWaterhouseCoopers in the Paris and Philadelphia offices (1989 to 1996). From 1996 to 1999, he worked for URGO Soins & Santé Laboratories as Head of Controlling, before moving up to Financial Director – International Operations of Laboratoires Fournier, a position he held until 2006. During 2007-2011, he held various positions as CFO with the Soufflet group, interim CFO with the NAOS group, then as senior consultant for I Care Environnement. Jean graduated from Paris IX Dauphine University in 1989 with a Magistère Sciences de Gestion and holds the D.E.S.C.F. In 2011, he received an Executive Masters degree in Corporate Social Responsibility from Mines ParisTech.
Consult Jean’s profile on LinkedIn
Jean-Louis Abitbol M.D., M.Sc.
Chief Medical Officer and Head of Development
Jean-Louis Abitbol brings over 30 year of experience in Research and Development to Inventiva Pharma. Before joining Inventiva, he was director of Research, Development and Global Medical Affairs at HRA Pharma, achieving the European OTC Switch of EllaOne® and the registration of Ketoconazole and mutual recognition of Metopirone in Cushing syndrome. From 2004 to 2012,Dr. Abitbol was CMO for Trophos and led the clinical development of Olesoxime and backup compounds in SMA, ALS, NASH, Neuropathic Pain and Cardiac Ischemia-Reperfusion Injury. Trophos has been acquired by Roche. Previously, he held positions of increasing responsibility in pharmaceutical companies in France and the USA (Pierre Fabre Médicament, Jouveinal/Parke-Davis/Pfizer and CERNEP-Synthélabo)
Jean-Louis Abitbol receivedan M.D. & M.Sc. in biomathematics and physiology from the Denis Diderot University and did his residency in Paris. He is a board certified Hepato-Gastroenterologist with a qualification in Oncology.
Consult Jean Louis’s profile on LinkedIn
Kristina Meyer, Ph.D.
Head of Business Development
Dr Meyer brings more than 15 years of commercial and business development experience in the international biotech industry to the company. Kristina joined Inventiva in 2015 from Oxford BioTherapeutics where she was responsible for the outlicensing of pre-clinical oncology assets, in-licensing of antibody arming technologies, oncology target discovery collaborations and alliance management. Prior to Oxford BioTherapeutics she worked at Evotec in the USA and the UK where she had regional commercial responsibility for the discovery alliance business across various therapeutic areas and territories including Europe and the West Coast of the USA. Previously she also held a number of commercial roles of increasing responsibility in the discovery information and informatics industry including Director of Business Development at Sertany and Thieme Medial Publishers. Dr Meyer holds a Ph.D. in organic chemistry from the University of Frankfurt, Germany, and conducted post-doctoral research at Yale University in New Haven, CT, USA.
Consult Kristina ’s profile on LinkedIn